SCHEMBL3340846

SCHEMBL3340846

O=C(NNc1nc2c(s1)=CC1=CC=CCC=21)c1cc2ccccc2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
HPGD P15428 1/20 0.39
BCAT1 P54687 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PYGL P06737 1/20 0.37
PYGM P11217 1/20 0.37
DRD2 P14416 2/20 0.37
DRD3 P35462 1/20 0.37
MIF P14174 1/20 0.36
EGFR P00533 2/20 0.36
PIK3CA P42336 2/20 0.36
HTR2C P28335 1/20 0.36
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4801854 0.78 FLT3 (0.35) GAAKDM4EALDH1A1MAPK1HPGD
SCHEMBL3340590 0.74 MAPT (0.46) GAALMNAKDM4EALDH1A1MAPK1
SCHEMBL1822990 0.74 NPC1 (0.47) GAAKDM4EALDH1A1HPGDNPC1
SCHEMBL3340839 0.69 ADORA1 (0.47) GAALMNAKDM4EALDH1A1MAPK1
SCHEMBL1819297 0.68 KDM1A (0.35) GAALMNAALDH1A1MAPK1HPGD
SCHEMBL4966967 0.65 NPC1 (0.37) LMNAKDM4EALDH1A1HPGDNPC1
SCHEMBL23468381 0.64 KDM4E (0.64) GAALMNAKDM4EALDH1A1MAPK1
SCHEMBL3337375 0.63 MAPT (0.61) GAALMNAKDM4EALDH1A1MAPK1
SCHEMBL20508273 0.62 GAA (0.62) GAALMNAKDM4EALDH1A1MAPK1
SCHEMBL3338690 0.62 RAB9A (0.55) GAALMNAKDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA GAA 76/4885LMNA 2315/4885KDM4E 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.